Sarepta

Edit

Statement of Changes in Beneficial Ownership (Form 4) (Sarepta Therapeutics Inc)

Public Technologies 28 Feb 2026

) FORM 4. Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b) ... See Instruction 10. UNITED STATES SECURITIES AND EXCHANGE COMMISSION ... 0.5 ... 2 ... Sarepta Therapeutics, Inc ... 6 ... Sarepta Therapeutics Inc.

Edit

Sarepta Therapeutics Announces Call for Applications for the 9th Annual Route 79, The Duchenne Scholarship Program

The Galveston Daily News 27 Feb 2026

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Feb 27, 2026-- ....

Edit

Sarepta Therapeutics: Q4 Earnings Snapshot

Caledonian Record 26 Feb 2026

CAMBRIDGE, Mass. (AP) — CAMBRIDGE, Mass. (AP) — Sarepta Therapeutics Inc. (SRPT) on Wednesday reported a loss of $412.2 million in its fourth quarter ....

Edit

Management Change/Compensation (Form 8-K) (Sarepta Therapeutics Inc)

Public Technologies 26 Feb 2026

). Item 5.02 ... On February 25, 2026, Douglas Ingram notified Sarepta Therapeutics, Inc ... Ingram's replacement. Attachments Original document Permalink. Disclaimer. Sarepta Therapeutics Inc.

Edit

Sarepta Therapeutics to Present New Long-Term and Safety Data Across Gene Therapy and Exon-Skipping Programs ...

The Galveston Daily News 26 Feb 2026

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Feb 26, 2026-- ....

Edit

Sarepta Therapeutics Announces Fourth Quarter and Full-Year 2025 Financial Results and Recent Corporate Developments

Business Wire 26 Feb 2026

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sarepta Therapeutics, Inc.

Edit

Q4 2025 Sarepta Earnings Presentation (Sarepta Therapeutics Inc)

Public Technologies 26 Feb 2026

©SAREPTA THERAPEUTICS, INC ... Sarepta regularly uses both GAAP and Non-GAAP results and expectations to assess its financial operating performance and cash requirement internally ... ©SAREPTA THERAPEUTICS, INC ... ©SAREPTA THERAPEUTICS, INC.

Edit

Sarepta Therapeutics Announces Fourth Quarter and Full-Year 2025 Financial Results and Recent Corporate Developments (Form 8-K) (Sarepta Therapeutics Inc)

Public Technologies 25 Feb 2026

-- (BUSINESS WIRE) -- February 25, 2026 -- Sarepta Therapeutics, Inc ... Sarepta is eligible to receive a $40 million milestone payment upon first commercial sale in Japan ... To report SUSPECTED ADVERSE REACTIONS, contact Sarepta Therapeutics, Inc.

Edit

Sarepta Therapeutics Announces Fourth Quarter and Full-Year 2025 Financial Results and Recent Corporate Developments (Sarepta Therapeutics Inc)

Public Technologies 25 Feb 2026

25, 2026-- Sarepta Therapeutics, Inc ... Sarepta is eligible to receive a $40 million milestone payment upon first commercial sale in Japan ... To report SUSPECTED ADVERSE REACTIONS, contact Sarepta Therapeutics, Inc ... About Sarepta Therapeutics.

Edit

Sarepta Therapeutics to Present at the TD Cowen 46th Annual Health Care Conference

The Galveston Daily News 24 Feb 2026

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Feb 24, 2026-- ....

Edit

Sarepta Therapeutics Announces Commercial Launch of ELEVIDYS in Japan

The Galveston Daily News 24 Feb 2026

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Feb 24, 2026-- ....

Edit

Initial Quarterly Holdings Report by Institutional Manager (Form 13F-HR) (Sarepta Therapeutics Inc)

Public Technologies 13 Feb 2026

). The Securities and Exchange Commission has not necessarily reviewed the information in this filing and has not determined if it is accurate and complete ... Washington, D.C. 20549. FORM 13F ... OMB APPROVAL ... Sarepta Therapeutics, Inc ... Sarepta Therapeutics Inc.

Edit

Sarepta Therapeutics to Announce Fourth Quarter and Full-Year 2025 Financial Results

The Galveston Daily News 11 Feb 2026

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Feb 11, 2026-- ....

Edit

Sarepta Therapeutics Announces Approval of Clinical Trial Application for SRP-1005, Its Investigational Treatment for Huntington’s Disease

Business Wire 04 Feb 2026

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sarepta Therapeutics, Inc ... Sarepta expects to initiate this ...

Edit

Sarepta Announces Positive Topline Three-Year EMBARK Results Showing ELEVIDYS Significantly Slows Disease Progression on Key ...

The Galveston Daily News 26 Jan 2026

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Jan 26, 2026-- ....

Podcasts:

Latest News for: sarepta

Statement of Changes in Beneficial Ownership (Form 4) (Sarepta Therapeutics Inc)

Sarepta Therapeutics Announces Call for Applications for the 9th Annual Route 79, The Duchenne Scholarship Program

Sarepta Therapeutics: Q4 Earnings Snapshot

Management Change/Compensation (Form 8-K) (Sarepta Therapeutics Inc)

Sarepta Therapeutics to Present New Long-Term and Safety Data Across Gene Therapy and Exon-Skipping Programs ...

Sarepta Therapeutics Announces Fourth Quarter and Full-Year 2025 Financial Results and Recent Corporate Developments

Q4 2025 Sarepta Earnings Presentation (Sarepta Therapeutics Inc)

Sarepta Therapeutics Announces Fourth Quarter and Full-Year 2025 Financial Results and Recent Corporate Developments (Form 8-K) (Sarepta Therapeutics Inc)

Sarepta Therapeutics Announces Fourth Quarter and Full-Year 2025 Financial Results and Recent Corporate Developments (Sarepta Therapeutics Inc)

Sarepta Therapeutics to Present at the TD Cowen 46th Annual Health Care Conference

Sarepta Therapeutics Announces Commercial Launch of ELEVIDYS in Japan

Initial Quarterly Holdings Report by Institutional Manager (Form 13F-HR) (Sarepta Therapeutics Inc)

Sarepta Therapeutics to Announce Fourth Quarter and Full-Year 2025 Financial Results

Sarepta Therapeutics Announces Approval of Clinical Trial Application for SRP-1005, Its Investigational Treatment for Huntington’s Disease

Sarepta Announces Positive Topline Three-Year EMBARK Results Showing ELEVIDYS Significantly Slows Disease Progression on Key ...

Article Search

EXPLORE WN.com